Considering the heterogeneity of human heart failure, identification of patients with prominent fibrosis and excessive activation of myocardial tTG-mediated matrix crosslinking may mark a subpopulation that may benefit from attenuation of enzymatic tTG actions. The gene discussed is TGM2; the disease is heart failure.